
DT-109 fatty liver drug repairs gut in animal study
On July 11, 2026, ScienceDaily reported that an experimental drug called DT-109 reversed severe fatty liver disease in animal studies by repairing the gut and blocking harmful toxins from reaching the liver (ScienceDaily). The finding points to a gut-first approach for metabolic dysfunction-associated steatohepatitis (MASH), a field long dominated by liver-targeted metabolic drugs. What ScienceDaily […]







